fbpx

ExpreS2ion Biotechnologies – Presentation of Q3 Quarterly Results

ExpreS2ion Biotechnologies - Presentation of Q3 Quarterly Results 18 NovemberNov 2021 11:00 - 11:30Online Event

ExpreS2ion Biotechnologies – Presentation of Q3 Quarterly Results

Watch live when the CEO of ExpreS2ion Biotechnologies, Bent Frandsen and the CFO, Keith Alexander presents the Q3 quarterly financial results. During the event it will be possible to ask questions.

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines. Currently the company is developing vaccines against Covid-19, breast cancer and Influenza.

Recently the company announced a subscription of their TO5 warrant program at 97.5%. This means the share capital of the company has risen by 6% and SEK 44.4 Millions before costs with the purpose of financing the continued development of their pipeline.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR / Corporate Visibility subscription agreement.

Deltag her

Du vil blive videresendt til en ekstern tilmeldingsside. 

Information

ExpreS2ion Biotechnologies - Presentation of Q3 Quarterly Results 18 NovemberNov 2021 11:00 - 11:30
ExpreS2ion Biotechnologies - Presentation of Q3 Quarterly Results Online Event
ExpreS2ion Biotechnologies
ExpreS2ion Biotechnologies - Presentation of Q3 Quarterly Results 18 NovemberNov 2021 11:00 - 11:30Online Event

ExpreS2ion Biotechnologies – Presentation of Q3 Quarterly Results

Watch live when the CEO of ExpreS2ion Biotechnologies, Bent Frandsen and the CFO, Keith Alexander presents the Q3 quarterly financial results. During the event it will be possible to ask questions.

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines. Currently the company is developing vaccines against Covid-19, breast cancer and Influenza.

Recently the company announced a subscription of their TO5 warrant program at 97.5%. This means the share capital of the company has risen by 6% and SEK 44.4 Millions before costs with the purpose of financing the continued development of their pipeline.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR / Corporate Visibility subscription agreement.

Information

ExpreS2ion Biotechnologies - Presentation of Q3 Quarterly Results 18 NovemberNov 2021 11:00 - 11:30
ExpreS2ion Biotechnologies - Presentation of Q3 Quarterly Results Online Event
ExpreS2ion Biotechnologies